Role of novel sodium glucose co-transporter-2 inhibitor enavogliflozin in type-2 diabetes: A systematic review and meta-analysis.

Deep Dutta,B G Harish,Beatrice Anne,Lakshmi Nagendra

Diabetes & metabolic syndrome（2023）

引用 1|浏览1

暂无评分

摘要

Enavogliflozin is a well tolerated and effective SGLT2i for T2DM and may be superior to dapagliflozin with regard to certain clinical aspects over 6 months clinical use.

查看译文

关键词

Enavogliflozin, Type-2 diabetes, Meta-analysis, Weight loss

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要